Clinical Trial Update: Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial evaluating TAK-101 for prevention of gluten-specific T cell activation in people with celiac disease on a gluten-free diet; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Celiac Disease

Drugs mentioned

• TAK-101

Snippet

Sponsor: Takeda | Conditions: Celiac Disease | Phase 2 | Status: COMPLETED